Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486352 · ClinicalTrials.gov registry record · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
A Phase 1 study of Endometrial Cancer, sponsored by Alliance Foundation Trials.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT04486352 is a Phase 1 study of Endometrial Cancer that is actively recruiting participants, run by Alliance Foundation Trials. The registered enrollment target is 148 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT04486352, a Phase 1 study of Endometrial Cancer, is actively recruiting participants, sponsored by Alliance Foundation Trials.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Ipatasertib
- DRUG Talazoparib
- DRUG Atezolizumab - 28 Day Cycle
- DRUG Trastuzumab emtansine
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
New Jersey
- Englewood Health - Englewood
- Atlantic Health Systems/Morristown Medical Center - Morristown
New York
- Roswell Park - Buffalo
- Weill Cornell Medicine - New York
District of Columbia
- Medstar Georgetown Cancer Institute - Washington D.C.
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas Cancer Center - Westwood
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486352
The ClinicalTrials.gov registry entry for NCT04486352 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04486352 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04486352 about?
NCT04486352 is a clinical study titled "A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer". This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening ...
What is the current status of trial NCT04486352?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2021-10-20. Estimated completion is 2027-10.
What conditions does trial NCT04486352 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04486352?
The interventions under investigation include: Bevacizumab (DRUG), Ipatasertib (DRUG), Talazoparib (DRUG), Atezolizumab - 28 Day Cycle (DRUG), Trastuzumab emtansine (DRUG).
Who is sponsoring clinical trial NCT04486352?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04486352 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.